Search for a doctor

Yucai Wang, M.D., Ph.D.

  1. Hematologist
  2. Hematologist / Oncologist
Request an Appointment

Publications

  1. Bock AM, Wenzl K, Novak JP, Stokes ME, Hopper MA, Krull JE, Dropik AR, Sarangi V, Ortiz M, Stong N, Huang CC, Maurer MJ, King RL, Farooq U, Wang Y, Witzig TE, Ansell SM, Habermann TM, Cerhan JR, Gandhi AK, Nowakowski G, Novak AJ. Molecular Features of Diffuse Large B-Cell Lymphoma Associated With Primary Treatment Resistance. Hematol Oncol. 2025 Jan; 43 (1):e70006
    View PubMed
  2. Munoz J, Tsang M, Wang Y, Phillips T. Challenges of treating mantle cell lymphoma in older adults. Leuk Lymphoma. 2024 Dec 11; 1-18 [Epub ahead of print]
    View PubMed
  3. Bommier C, Link BK, Gysbers BJ, Maurer MJ, Larson MC, Khurana A, Wang Y, Thompson CA, Chihara D, Alderuccio JP, Koff JL, Epperla N, Conconi A, Lossos IS, Nowakowski GS, Feldman AL, Habermann TM, King RL, Cerhan JR. Transformation in marginal zone lymphoma: results from a prospective cohort and a meta-analysis of the literature. Blood Adv. 2024 Dec 10; 8 (23):5939-5948
    View PubMed
  4. Hampel PJ, Rabe KG, Wang Y, Hwang SR, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Tsang M, Hilal T, Parrondo R, Bailen RJ, Schwager SM, Hanson CA, Braggio E, Slager SL, Shi M, Zepeda-Mendoza CJ, Van Dyke DL, Shanafelt TD, King RL, Call TG, Kay NE, Ding W, Parikh SA. Incidence of Richter transformation of chronic lymphocytic leukemia/small lymphocytic lymphoma in the targeted therapy era. Leukemia. 2024 Dec 10 [Epub ahead of print]
    View PubMed
  5. Stanchina MD, Montoya S, Danilov AV, Castillo JJ, Alencar AJ, Chavez JC, Cheah CY, Chiattone C, Wang Y, Thompson M, Ghia P, Taylor J, Alderuccio JP. Navigating the changing landscape of BTK-targeted therapies for B cell lymphomas and chronic lymphocytic leukaemia. Nat Rev Clin Oncol. 2024 Dec; 21 (12):867-887 Epub 2024 Nov 01
    View PubMed
  6. Day JR, Larson MC, Durani U, Koff JL, Wang Y, Habermann TM, Lossos IS, Nastoupil LJ, Strouse CS, Chihara D, Martin P, Leonard JP, Cohen JB, Kahl BS, Ruan J, Burack R, Friedberg JW, Cerhan JR, Flowers CR, Link BL, Maurer MJ, Casulo C. Treatment Patterns and Outcomes in Follicular Lymphoma with POD24: An Analysis from The LEO Consortium. Blood Adv. 2024 Nov 27 [Epub ahead of print]
    View PubMed
  7. Atallah-Yunes SA, Wang Y. Dual epigenetic therapy plus chemotherapy in peripheral T cell lymphoma with T follicular helper phenotype. Med. 2024 Nov 8; 5 (11):1335-1337
    View PubMed
  8. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous Stem Cell Transplant in Fit Patients With Late Relapsed Diffuse Large B-Cell Lymphoma That Responded to Salvage Chemotherapy. Transplant Cell Ther. 2024 Oct; 30 (10):1001.e1-1001.e12 Epub 2024 July 10
    View PubMed
  9. Wang JF, Wang Y. Evaluating pirtobrutinib for the treatment of relapsed or refractory mantle cell lymphoma. Expert Rev Hematol. 2024 Oct; 17 (10):651-659 Epub 2024 Aug 08
    View PubMed
  10. Koehler AB, Rabe KG, Crusan DJ, Call TG, Achenbach SJ, Hampel PJ, Kenderian SS, Leis JF, Wang Y, Muchtar E, Tsang M, Hilal T, Parrondo R, Bailey KR, Ding W, Bailen R, Schwager SM, Shi M, Hanson CA, Slager SL, Kay NE, Ashrani AA, Parikh SA. Incidence, risk factors, and outcomes of patients with monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia who develop venous thromboembolism. J Thromb Haemost. 2024 Sep 27 Epub 2024 Sept 27
    View PubMed
  11. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Alhaj Moustafa M, Murthy HS, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Outcomes of patients with R/R B-cell NHL and limited (<5 sites) pre-CART disease bridged with or without radiotherapy. Blood Adv. 2024 Sep 24; 8 (18):4877-4885
    View PubMed
  12. Wierda WG, Shah NN, Cheah CY, Lewis D, Hoffmann MS, Coombs CC, Lamanna N, Ma S, Jagadeesh D, Munir T, Wang Y, Eyre TA, Rhodes JM, McKinney M, Lech-Maranda E, Tam CS, Jurczak W, Izutsu K, Alencar AJ, Patel MR, Seymour JF, Woyach JA, Thompson PA, Abada PB, Ho C, McNeely SC, Marella N, Nguyen B, Wang C, Ruppert AS, Nair B, Liu H, Tsai DE, Roeker LE, Ghia P. Pirtobrutinib, a highly selective, non-covalent (reversible) BTK inhibitor in patients with B-cell malignancies: analysis of the Richter transformation subgroup from the multicentre, open-label, phase 1/2 BRUIN study. Lancet Haematol. 2024 Sep; 11 (9):e682-e692 Epub 2024 July 18
    View PubMed
  13. Khurana A, Rosenthal AC, Mohty R, Gaddam M, Bansal R, Hathcock MA, Nedved AN, Durani U, Iqbal M, Wang Y, Paludo J, Villasboas JC, Dingli D, Kourelis T, Leung N, Alkhateeb H, Ruff MW, Gallo de Moraes A, Vergidis P, Herrmann J, Kenderian SS, Bennani NN, Johnston PB, Ansell SM, Lin Y. Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management. Blood Cancer J 2024 Aug 12; 14 (1):136
    View PubMed
  14. Okcu I, Wang Y, Bock AM, Zhou J, Moustafa MA, Tun HW, Rosenthal AC, Johnston PB, Baidoun F, Khurana A, Kabat BF, King RL, Habermann TM, Nowakowski GS. Incidence of Central Nervous System Relapse in Primary Mediastinal Large B-Cell Lymphoma: Implications for Central Nervous System Prophylaxis. Clin Lymphoma Myeloma Leuk. 2024 Aug 2 Epub 2024 Aug 02
    View PubMed
  15. Laoruangroj C, Habermann TM, Wang Y, King RL, Lester SC, Thompson CA, Witzig TE. Should All Patients With Stage IE Gastric Mucosa-Associated Lymphoid Tissue Lymphoma Receive Antibiotic Eradication Therapy for Helicobacter pylori? JCO Oncol Pract. 2024 Aug; 20 (8):1103-1108 Epub 2024 May 07
    View PubMed
  16. Bock AM, Mwangi R, Wang Y, Khurana A, Maurer MJ, Ayers A, Kahl BS, Martin P, Cohen JB, Casulo C, Lossos IS, Farooq U, Ayyappan S, Reicks T, Habermann TM, Witzig TE, Flowers CR, Cerhan JR, Nastoupil LJ, Nowakowski GS. Defining primary refractory large B-cell lymphoma. Blood Adv. 2024 Jul 9; 8 (13):3402-3415
    View PubMed
  17. Maurer MJ, Casulo C, Larson MC, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan JR, Link BK, Flowers CR. Matching-adjusted indirect comparison from the Lymphoma Epidemiology of Outcomes Consortium for Real World Evidence (LEO CReWE) study to a clinical trial of mosunetuzumab in relapsed or refractory follicular lymphoma. Haematologica. 2024 Jul 1; 109 (7):2177-2185 Epub 2024 July 01
    View PubMed
  18. Tun AM, Wang Y, Maliske S, Micallef I, Inwards DJ, Habermann TM, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Autologous stem cell transplant in fit patients with refractory or early relapsed diffuse large B-cell lymphoma that responded to salvage chemotherapy. Haematologica. 2024 Jul 1; 109 (7):2186-2195 Epub 2024 July 01
    View PubMed
  19. Wang H, Tian S, Secreto CR, Sinha S, Shi M, Call T, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, VanDyke DL, Klee EW, Slager SL, Braggio E, Yan H, Ding W. Clonal dynamics of Richter transformation in chronic lymphocytic leukemia. Hematol Oncol 2024 Jul; 42 (4):e3282
    View PubMed
  20. Roeker LE, Coombs CC, Shah NN, Jurczak W, Woyach JA, Cheah CY, Patel K, Maddocks K, Wang Y, Zinzani PL, Munir T, Koh Y, Thompson MC, Muehlenbein CE, Wang C, Sizelove R, Abhyankar S, Hasanabba S, Tsai DE, Eyre TA, Wang M. Safety of Extended Pirtobrutinib Exposure in Relapsed and/or Refractory B-Cell Malignancies. Acta Haematol. 2024 Jun 5; 1-17 Epub 2024 June 05
    View PubMed
  21. Truong HL, Barreto JN, Mara KC, Hampel PJ, Micallef IN, Nowakowski GS, Thanarajasingam G, Thompson CA, Wang Y, Witzig TE, Herrmann SM, Leung N. Rechallenge With High-Dose Methotrexate After Treatment With Glucarpidase in Adult Patients With Lymphoma. JCO Oncol Pract. 2024 Jun; 20 (6):797-807 Epub 2024 Feb 26
    View PubMed
  22. Hampel PJ, Swaminathan M, Rogers KA, Parry EM, Burger JA, Davids MS, Ding W, Ferrajoli A, Hyak JM, Jain N, Kenderian SS, Wang Y, Wierda WG, Woyach JA, Parikh SA, Thompson PA. A multicenter study of venetoclax-based treatment for patients with Richter transformation of chronic lymphocytic leukemia. Blood Adv. 2024 May 28; 8 (10):2342-2350
    View PubMed
  23. Rejeski K, Wang Y, Hansen DK, Iacoboni G, Bachy E, Bansal R, Penack O, Muller F, Bethge W, Munoz J, Mohty R, Bucklein VL, Barba P, Locke FL, Lin Y, Jain MD, Subklewe M. Applying the EHA/EBMT grading for ICAHT after CAR-T: comparative incidence and association with infections and mortality. Blood Adv. 2024 Apr 23; 8 (8):1857-1868
    View PubMed
  24. Kang DW, Wang L, Short NJ, Ferrajoli A, Wang Y, Zhou S, Shen C. Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42 (4):409-418 Epub 2024 Jan 06
    View PubMed
  25. Bansal R, Vergidis P, Tosh PK, Wilson J, Hathcock M, Khurana A, Bennani NN, Paludo J, Villasboas JC, Wang Y, Ansell SM, Johnston PB, Freeman C, Lin Y. Serial Evaluation of Preimmunization Antibody Titers in Lymphoma Patients Receiving Chimeric Antigen Receptor T Cell Therapy. Transplant Cell Ther. 2024 Apr; 30 (4):455.e1-455.e7 Epub 2024 Feb 10
    View PubMed
  26. Christopoulos G, Attia ZI, Achenbach SJ, Rabe KG, Call TG, Ding W, Leis JF, Muchtar E, Kenderian SS, Wang Y, Hampel PJ, Koehler AB, Kay NE, Kapoor P, Slager SL, Shanafelt TD, Noseworthy PA, Friedman PA, Herrmann J, Parikh SA. Artificial Intelligence Electrocardiography to Predict Atrial Fibrillation in Patients With Chronic Lymphocytic Leukemia. JACC CardioOncol. 2024 Apr; 6 (2):251-263 Epub 2024 Apr 16
    View PubMed
  27. Chohan KL, Bansal R, Hathcock MA, Paludo J, Bennani NN, Johnston PB, Khurana A, Durani U, Wang Y, Ruff MW, Villasboas Bisneto JC, Ansell SM, Lin Y, Kenderian SS. Real-world associations of cytokine release syndrome and neurotoxicity with efficacy in patients receiving anti-CD-19 chimeric antigen receptor T-cell therapy for large B-cell lymphoma: the Mayo Clinic experience. Leuk Lymphoma. 2024 Mar; 65 (3):389-393 Epub 2023 Nov 30
    View PubMed
  28. Cerhan JR, Maurer MJ, Link BK, Feldman AL, Habermann TM, Jaye DL, Burack WR, McDonnell TJ, Vega F, Chapman JR, Syrbu S, Vij KR, Inghirami G, Leonard JP, Bernal-Mizrachi L, Farooq U, Witzig TE, Weiner GJ, Wang Y, Alderuccio JP, Slager SL, Larson MC, Riska SM, Gysbers BJ, Lunde JJ, Reicks TW, Ayers AA, O'Leary CB, Yost KJ, Liu H, Nowakowski GS, Ruan J, Chihara D, Koff JL, Casulo C, Thompson CA, Cohen JB, Kahl BS, Nastoupil LJ, Lossos IS, Friedberg JW, Martin P, Flowers CR. The Lymphoma Epidemiology of Outcomes cohort study: Design, baseline characteristics, and early outcomes. Am J Hematol. 2024 Mar; 99 (3):408-421 Epub 2024 Jan 13
    View PubMed
  29. Bock AM, Gile JJ, Larson MC, Poonsombudlert K, Tawfiq RK, Maliske S, Maurer MJ, Kabat BF, Paludo J, Inwards DJ, Ayyappan S, Link BK, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS, Cerhan JR, Farooq U, Wang Y. Evolving treatment patterns and improved outcomes in relapsed/refractory mantle cell lymphoma: a prospective cohort study. Blood Cancer J. 2023 Nov 13; 13 (1):169
    View PubMed
  30. Kosydar SR, Parikh SA, Lester SC, Rabe KG, Ding W, Burlile JF, Kenderian SS, Wang Y, Muchtar E, Koehler AB, Schwager SM, Slager SL, Kay NE, Call TG, Breen WG, Hampel PJ. Safety of radiotherapy for second primary malignancies in patients with chronic lymphocytic leukemia receiving concurrent novel agent treatment. Am J Hematol 2023 Nov; 98 (11):E318-E321 Epub 2023 Aug 24
    View PubMed
  31. Rejeski K, Wang Y, Albanyan O, Munoz J, Sesques P, Iacoboni G, Lopez-Corral L, Ries I, Bucklein VL, Mohty R, Dreyling M, Baluch A, Shah B, Locke FL, Hess G, Barba P, Bachy E, Lin Y, Subklewe M, Jain MD. The CAR-HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL. Am J Hematol. 2023 Nov; 98 (11):1699-1710 Epub 2023 Aug 16
    View PubMed
  32. Saifi O, Breen WG, Lester SC, Rule WG, Stish BJ, Rosenthal A, Munoz J, Lin Y, Bansal R, Hathcock MA, Johnston PB, Ansell SM, Paludo J, Khurana A, Villasboas JC, Wang Y, Iqbal M, Moustafa MA, Murthy HS, Kharfan-Dabaja MA, Peterson JL, Hoppe BS. Consolidative radiotherapy for residual fluorodeoxyglucose activity on day +30 post CAR T-cell therapy in non-Hodgkin lymphoma. Haematologica. 2023 Nov 01; 108(11):2982-2992.
    View PubMed
  33. Wang ML, Jurczak W, Zinzani PL, Eyre TA, Cheah CY, Ujjani CS, Koh Y, Izutsu K, Gerson JN, Flinn I, Tessoulin B, Alencar AJ, Ma S, Lewis D, Lech-Maranda E, Rhodes J, Patel K, Maddocks K, Lamanna N, Wang Y, Tam CS, Munir T, Nagai H, Hernandez-Ilizaliturri F, Kumar A, Fenske TS, Seymour JF, Zelenetz AD, Nair B, Tsai DE, Balbas M, Walgren RA, Abada P, Wang C, Zhao J, Mato AR, Shah NN. Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. J Clin Oncol. 2023 Aug 20; 41 (24):3988-3997 Epub 2023 May 16
    View PubMed
  34. Breen WG, Young JR, Hathcock MA, Kowalchuk RO, Thorpe MP, Bansal R, Khurana A, Bennani NN, Paludo J, Bisneto JV, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic PET/CT analysis of aggressive Non-Hodgkin lymphoma prior to Axicabtagene Ciloleucel CAR-T infusion: predictors of progressive disease, survival, and toxicity. Blood Cancer J. 2023 Aug 18; 13 (1):127
    View PubMed
  35. Rejeski K, Hansen DK, Bansal R, Sesques P, Ailawadhi S, Logue JM, Bräunlein E, Cordas Dos Santos DM, Freeman CL, Alsina M, Theurich S, Wang Y, Krackhardt AM, Locke FL, Bachy E, Jain MD, Lin Y, Subklewe M. The CAR-HEMATOTOX score as a prognostic model of toxicity and response in patients receiving BCMA-directed CAR-T for relapsed/refractory multiple myeloma. J Hematol Oncol. 2023 Jul 31; 16(1):88.
    View PubMed
  36. Wiedmeier-Nutor JE, Iqbal M, Rosenthal AC, Bezerra ED, Garcia-Robledo JE, Bansal R, Johnston PB, Hathcock M, Larsen JT, Bergsagel PL, Wang Y, Reeder CB, Leis JF, Fonseca R, Palmer JM, Gysbers BJ, Mwangi R, Warsame RM, Kourelis T, Hayman SR, Dingli D, Kapoor P, Kumar SK, Durani U, Villasboas JC, Paludo J, Bennani NN, Nowakowski G, Ansell SM, Castro JE, Kharfan-Dabaja MA, Lin Y, Vergidis P, Murthy HS, Munoz J. Response to COVID-19 Vaccination Post-CAR T Therapy in Patients With Non-Hodgkin Lymphoma and Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2023 Jun; 23 (6):456-462 Epub 2023 Mar 07
    View PubMed
  37. Ng WL, Wang Y, Bock AM, Jevremovic D, Wang ML, Nowakowski GS. Review of management options for mantle cell lymphoma in pregnancy. Leuk Lymphoma 2023 Jun; 64 (6):1194-1198 Epub 2023 Apr 10
    View PubMed
  38. Wang Y, Jain P, Locke FL, Maurer MJ, Frank MJ, Munoz JL, Dahiya S, Beitinjaneh AM, Jacobs MT, Mcguirk JP, Vose JM, Goy A, Andreadis C, Hill BT, Dorritie KA, Oluwole OO, Deol A, Paludo J, Shah B, Wang T, Banerjee R, Miklos DB, Rapoport AP, Lekakis L, Ghobadi A, Neelapu SS, Lin Y, Wang ML, Jain MD. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium. J Clin Oncol. 2023 May 10; 41 (14):2594-2606 Epub 2023 Feb 08
    View PubMed
  39. Bezerra ED, Iqbal M, Munoz J, Khurana A, Wang Y, Maurer MJ, Bansal R, Hathcock MA, Bennani N, Murthy HS, Rosenthal AC, Paludo J, Villasboas JC, Johnston PB, Habermann TM, Ansell SM, Castro JE, Witzig TE, Kharfan-Dabaja MA, Nowakowski GS, Lin Y. Barriers to enrollment in clinical trials of patients with aggressive B-cell NHL that progressed after CAR T-cell therapy. Blood Adv. 2023 Apr 25; 7 (8):1572-1576
    View PubMed
  40. Tun AM, Wang Y, Matin A, Inwards DJ, Habermann TM, Micallef I, Johnston PB, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Tun HW, Cerhan JR, Witzig TE, Nowakowski GS, Ansell SM. Outcomes of Patients With Classic Hodgkin Lymphoma Who Relapsed After Autologous Stem Cell Transplant. Hemasphere. 2023 Apr; 7 (4):e869 Epub 2023 Apr 04
    View PubMed
  41. Powell MZ, Mara KC, Bansal R, Hathcock MA, Khurana A, Bennani NN, Wang Y, Paludo J, Bisneto JV, Ansell SM, Johnston PB, Lin Y, Barreto JN. Procalcitonin as a biomarker for predicting bacterial infection in chimeric antigen receptor T-cell therapy recipients. Cancer Med. 2023 Apr; 12 (8):9228-9235 Epub 2023 Feb 08
    View PubMed
  42. McLaughlin N, Wang Y, Witzig T, Villasboas J, Habermann T, Inwards D, Bennani N, Thanarajasingam G, Nowakowski G, Porrata L, Thompson C, Micallef I, Johnston P, Ansell S, Paludo J. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023 Feb; 64 (2):371-377 Epub 2022 Nov 23
    View PubMed
  43. Desai SH, Mwangi R, Smith AN, Maurer MJ, Farooq U, King RL, Cerhan JR, Feldman AL, Habermann TM, Thompson CA, Wang Y, Ansell SM, Witzig TE, Nowakowski GS. Cell of origin is not associated with outcomes of relapsed or refractory diffuse large B cell lymphoma. Hematol Oncol. 2023 Feb; 41 (1):39-49 Epub 2022 Nov 07
    View PubMed
  44. Acosta-Medina AA, Johnson IM, Bansal R, Hathcock M, Kenderian SJ, Durani U, Khurana A, Wang Y, Paludo J, Villasboas JC, Bennani NN, Johnston PB, Ansell SM, Lin Y, Alkhateeb HB. Pre-lymphodepletion & infusion endothelial activation and stress index as predictors of clinical outcomes in CAR-T therapy for B-cell lymphoma. Blood Cancer J 2023 Jan 5; 13 (1):7 Epub 2023 Jan 05
    View PubMed
  45. Desai SH, Mwangi R, Ng WL, King RL, Maurer MJ, Cerhan JR, Feldman AL, Farooq U, Mou E, Habermann TM, Thompson CA, Wang Y, Witzig TE, Nowakowski GS. Increasing tissue requirements in lymphoma trials may exclude patients with high-risk disease or worse prognosis. Blood Adv. 2022 Dec 27; 6 (24):6180-6186
    View PubMed
  46. O'Donoghue DF, Truong HL, Finnes HD, McDonald JS, May HP, Ansell SM, Bennani NN, Habermann TM, Inwards DJ, Johnston PB, Khurana A, Lin Y, Micallef IN, Nowakowski GS, Paludo J, Porrata LF, Thanarajasingam G, Thompson CA, Villasboas JC, Wang Y, Witzig TE, Leung N. High-Dose Methotrexate in Patients With Lymphoma: Predictors of a Complicated Course. JCO Oncol Pract. 2022 Dec; 18 (12):e1908-e1917 Epub 2022 Oct 14
    View PubMed
  47. Salles G, Schuster SJ, Dreyling M, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith SM, Jimenez-Ubieto A, Davis KL, Anjos C, Chu J, Zhang J, Lobetti Bodoni C, Thieblemont C, Fowler NH, Dickinson M, Martinez-Lopez J, Wang Y, Link BK. Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma. Blood Adv. 2022 Nov 22; 6 (22):5835-5843
    View PubMed
  48. Eyre TA, Shah NN, Dreyling M, Jurczak W, Wang Y, Cheah CY, Song Y, Gandhi M, Chay C, Sharman J, Andorsky DJ, Messersmith HM, Ruppert AS, Muthig VA, Ito R, Wang ML. BRUIN MCL-321: phase III study of pirtobrutinib versus investigator choice of BTK inhibitor in BTK inhibitor naive mantle cell lymphoma. Future Oncol. 2022 Nov; 18 (36):3961-3969 Epub 2022 Nov 15
    View PubMed
  49. Qi X, Zhou S, Wang Y, Peterson C. Bayesian sparse modeling to identify high-risk subgroups in meta-analysis of safety data. Res Synth Methods. 2022 Nov; 13 (6):807-820 Epub 2022 Aug 26
    View PubMed
  50. Beitinjaneh A, Kaufman A, Wang Y, Jain P, Srour SA, Wang M. Is There Still a Role for Transplant for Patients with Mantle Cell Lymphoma (MCL) in the Era of CAR-T Cell Therapy? Curr Treat Options Oncol. 2022 Nov; 23 (11):1614-1625 Epub 2022 Oct 13
    View PubMed
  51. Munoz JL, Wang Y, Jain P, Wang M. BTK Inhibitors and CAR T-Cell Therapy in Treating Mantle Cell Lymphoma-Finding a Dancing Partner. Curr Oncol Rep. 2022 Oct; 24 (10):1299-1311 Epub 2022 May 21
    View PubMed
  52. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Parrondo R, Schwager SM, Shi M, Braggio E, Slager SL, Kay NE, Parikh SA. Combined ibrutinib and venetoclax for treatment of patients with ibrutinib-resistant or double-refractory chronic lymphocytic leukaemia. Br J Haematol. 2022 Oct; 199 (2):239-244 Epub 2022 July 16
    View PubMed
  53. Tun AM, Khurana A, Mwangi R, Link BK, Wang Y, Feldman AL, Thompson CA, Novak AJ, Villasboas JC, Thanarajasingam G, Farooq U, Syrbu S, Nowakowski GS, Witzig TE, Ansell SM, Rimsza LM, Cerhan JR, Habermann TM, Maurer MJ. Causes of death in low-grade B-cell lymphomas in the rituximab era: a prospective cohort study. Blood Adv. 2022 Sep 13; 6 (17):5210-5221
    View PubMed
  54. Tun AM, Maliske S, Wang Y, Inwards DJ, Habermann TM, Micallef I, Porrata L, Paludo J, Bisneto JV, Rosenthal A, Kharfan-Dabaja MA, Ansell SM, Nowakowski GS, Farooq U, Johnston PB. Progression-Free Survival at 24 Months as A Landmark After Autologous Stem Cell Transplant in Relapsed or Refractory Diffuse Large B-cell Lymphoma. Transplant Cell Ther. 2022 Sep; 28 (9):610-617 Epub 2022 June 22
    View PubMed
  55. Hampel PJ, Rabe KG, Call TG, Ding W, Leis JF, Chanan-Khan AA, Kenderian SS, Muchtar E, Wang Y, Ailawadhi S, Koehler AB, Parrondo R, Schwager SM, Sher T, Hanson CA, Shi M, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Clinical outcomes in patients with chronic lymphocytic leukemia with disease progression on ibrutinib. Blood Cancer J. 2022 Sep 1; 12 (9):124 Epub 2022 Sept 01
    View PubMed
  56. Farooqui N, Sy-Go JPT, Miao J, Mehta R, Vaughan LE, Bennani NN, Wang Y, Bansal R, Hathcock MA, Hayman SR, Johnston PB, Villasboas JC, Paludo J, Ansell SM, Leung N, Lin Y, Herrmann SM. Incidence and Risk Factors for Acute Kidney Injury After Chimeric Antigen Receptor T-Cell Therapy. Mayo Clin Proc. 2022 Jul; 97 (7):1294-1304
    View PubMed
  57. Salles G, Schuster SJ, Fischer L, Kuruvilla J, Patten PEM, von Tresckow B, Smith S, Jimenez-Ubieto A, Davis KL, Nagar S, Zhang J, Bollu V, Jousseaume E, Ramos R, Wang Y, Link BK. A Retrospective Cohort Study of Treatment Outcomes of Adult Patients With Relapsed or Refractory Follicular Lymphoma (ReCORD-FL). Hemasphere. 2022 Jul; 6 (7):e745 Epub 2022 June 21
    View PubMed
  58. Bansal R, Novo M, Al Saleh AS, Guerrico AG, Zhang H, Shao Z, Babadi E, Martinez KE, McCoy GA, Hathcock MA, Khurana A, Bennani NN, Paludo J, Wang Y, Ansell SM, Johnston PB, Villasboas JC, Lin Y. Peak absolute lymphocyte count after CAR-T infusion predicts clinical response in aggressive lymphoma. Am J Hematol 2022 Jul; 97 (7):E241-E244 Epub 2022 Apr 14
    View PubMed
  59. Melody M, Gandhi S, Saunders H, Abdel-Rahman Z, Hastings J, Lengerke Diaz P, Gannon N, Truong T, Hathcock M, Khurana A, Johnston P, Ansell S, Bennani N, Paludo J, Bisneto JV, Wang Y, Rosenthal A, Foran J, Ayala E, Murthy HS, Roy V, Castro JE, Lin Y, Kharfan-Dabaja MA. Incidence of thrombosis in relapsed/refractory B-cell lymphoma treated with axicabtagene ciloleucel: Mayo Clinic experience. Leuk Lymphoma. 2022 Jun; 63(6):1363-1368. Epub 2022 Feb 03.
    View PubMed
  60. Deshpande A, Wang Y, Munoz J, Jain P. Brexucabtagene autoleucel: a breakthrough in the treatment of mantle cell lymphoma. Drugs Today (Barc). 2022 Jun; 58 (6):283-298
    View PubMed
  61. Desai SH, Pederson L, LaPlant B, Mwangi R, Maurer M, Young JR, Macon WR, King RL, Wang Y, Cerhan JR, Feldman A, Inwards DJ, Micallef I, Johnston P, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. PET2 response associated with survival in newly diagnosed diffuse large B-cell lymphoma: results of two independent prospective cohorts. Blood Cancer J. 2022 May 3; 12 (5):78 Epub 2022 May 03
    View PubMed
  62. Wang H, Tian S, Zhao Q, Blumenschein W, Yearley JH, Secreto CR, Sinha S, Call TG, Wang Y, Parikh SA, Kenderian SS, He R, Leis JF, Shi M, Van Dyke DL, Kay NE, Slager SL, Braggio E, Yan H, Ding W. Differential transcriptomic profiling in ibrutinib-naive versus ibrutinib-resistant Richter syndrome. Hematol Oncol 2022 Apr; 40 (2):302-306 Epub 2021 Dec 03
    View PubMed
  63. Casulo C, Larson MC, Lunde JJ, Habermann TM, Lossos IS, Wang Y, Nastoupil LJ, Strouse C, Chihara D, Martin P, Cohen JB, Kahl BS, Burack WR, Koff JL, Mun Y, Masaquel A, Wu M, Wei MC, Shewade A, Li J, Cerhan J, Flowers CR, Link BK, Maurer MJ. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study. Lancet Haematol. 2022 Apr; 9 (4):e289-e300
    View PubMed
  64. Breen WG, Hathcock MA, Young JR, Kowalchuk RO, Bansal R, Khurana A, Bennani NN, Paludo J, Villasboas Bisneto JC, Wang Y, Ansell SM, Peterson JL, Johnston PB, Lester SC, Lin Y. Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT. J Hematol Oncol 2022 Mar 26; 15 (1):36
    View PubMed
  65. Castellino A, Wang Y, Larson MC, Maurer MJ, Link BK, Farooq U, Feldman AL, Syrbu SI, Habermann TM, Paludo J, Inwards DJ, Witzig TE, Ansell SM, Allmer C, Slager SL, Cohen JB, Martin P, Cerhan JR, Nowakowski GS. Evolving frontline immunochemotherapy for mantle cell lymphoma and the impact on survival outcomes. Blood Adv. 2022 Feb 22; 6 (4):1350-1360
    View PubMed
  66. Bock AM, Nowakowski GS, Wang Y. Bispecific Antibodies for Non-Hodgkin Lymphoma Treatment. Curr Treat Options Oncol. 2022 Feb; 23 (2):155-170 Epub 2022 Feb 19
    View PubMed
  67. King RL, Gupta A, Kurtin PJ, Ding W, Call TG, Rabe KG, Kenderian SS, Leis JF, Wang Y, Schwager SM, Slager SL, Kay NE, Koehler A, Ansell SM, Inwards DJ, Habermann TM, Shi M, Hanson CA, Howard MT, Parikh SA. Chronic lymphocytic leukemia (CLL) with Reed-Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter? Blood Cancer J. 2022 Jan 28; 12 (1):18
    View PubMed
  68. Wang Y, Zhou S, Qi X, Yang F, Maurer MJ, Habermann TM, Witzig TE, Wang ML, Nowakowski GS. Efficacy of front-line immunochemotherapy for follicular lymphoma: a network meta-analysis of randomized controlled trials. Blood Cancer J. 2022 Jan 5; 12 (1):1 Epub 2022 Jan 05
    View PubMed
  69. Saifi O, Breen WG, Lester SC, Rule WG, Stish B, Rosenthal A, Munoz J, Herchko SM, Murthy HS, Lin Y, Bansal R, Hathcock MA, Bennani NN, Paludo J, Wang Y, Khurana A, Bisneto JCV, Johnston PB, Ansell SM, Iqbal M, Tun H, Ayala E, Kharfan-Dabaja MA, Hoppe BS, Peterson JL. Does bridging radiation therapy affect the pattern of failure after CAR T-cell therapy in non-Hodgkin lymphoma? Radiother Oncol. 2022 Jan; 166:171-179. Epub 2021 Dec 07.
    View PubMed
  70. Munoz J, Wang Y, Jain P, Wang M. Zanubrutinib in lymphoproliferative disorders: a comprehensive review. Ther Adv Hematol. 2022; 13:20406207221093980 Epub 2022 May 27
    View PubMed
  71. Muchtar E, Koehler AB, Johnson MJ, Rabe KG, Ding W, Call TG, Leis JF, Kenderian SS, Hayman SR, Wang Y, Hampel PJ, Holets MA, Darby HC, Slager SL, Kay NE, Miao C, Canniff J, Whitaker JA, Levin MJ, Schmid DS, Kennedy RB, Weinberg A, Parikh SA. Humoral and cellular immune responses to recombinant herpes zoster vaccine in patients with chronic lymphocytic leukemia and monoclonal B cell lymphocytosis. Am J Hematol. 2022 Jan 1; 97 (1):90-98 Epub 2021 Nov 05
    View PubMed
  72. Yang F, Wang Y, Tang L, Mansfield AS, Adjei AA, Leventakos K, Duma N, Wei J, Wang L, Liu B, Molina JR. Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis. Front Oncol. 2022; 12:955440 Epub 2022 Aug 16
    View PubMed
  73. Yang F, Wang JF, Wang Y, Liu B, Molina JR. Comparative Analysis of Predictive Biomarkers for PD-1/PD-L1 Inhibitors in Cancers: Developments and Challenges. Cancers (Basel). 2021 Dec 27; 14 (1)
    View PubMed
  74. Kraft RM, Ansell SM, Villasboas JC, Bennani NN, Wang Y, Habermann TM, Thanarajasingam G, Lester SC, Macon W, Inwards DJ, Porrata LF, Micallef IN, Witzig TE, Thompson CA, Johnston PB, Nowakowski GS, Lin Y, Paludo J. Outcomes in primary cutaneous diffuse large B-cell lymphoma, leg type. Hematol Oncol. 2021 Dec; 39(5):658-663. Epub 2021 Aug 28.
    View PubMed
  75. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Braksick SA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. Age defining immune effector cell associated neurotoxicity syndromes in aggressive large B cell lymphoma patients treated with axicabtagene ciloleucel. Am J Hematol 2021 Nov 1; 96 (11):E427-E430 Epub 2021 Sept 07
    View PubMed
  76. Desai SH, LaPlant B, Macon WR, King RL, Wang Y, Inwards DJ, Micallef I, Johnston PB, Porrata LF, Ansell SM, Habermann TM, Witzig TE, Nowakowski GS. Lenalidomide in combination with R-CHOP produces high response rates and progression-free survival in new, untreated diffuse large B-cell lymphoma transformed from follicular lymphoma: results from the Phase 2 MC078E study. Blood Cancer J. 2021 Sep 25; 11 (9):160 Epub 2021 Sept 25
    View PubMed
  77. Loree JM, Wang Y, Syed MA, Sorokin AV, Coker O, Xiu J, Weinberg BA, Vanderwalde AM, Tesfaye A, Raymond VM, Miron B, Tarcic G, Zelichov O, Broaddus RR, Ng PKS, Jeong KJ, Tsang YH, Mills GB, Overman MJ, Grothey A, Marshall JL, Kopetz S. Clinical and Functional Characterization of Atypical KRAS/NRAS Mutations in Metastatic Colorectal Cancer. Clin Cancer Res. 2021 Aug 15; 27 (16):4587-4598 Epub 2021 June 11
    View PubMed
  78. Wang Y, Achenbach SJ, Rabe KG, Shanafelt TD, Call TG, Ding W, Kenderian SS, Muchtar E, Leis JF, Koehler AB, Schwager SM, Cerhan JR, Slager SL, Kay NE, Parikh SA. Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index. Blood Cancer J 2021 Aug 5; 11 (8):140 Epub 2021 Aug 05
    View PubMed
  79. Arushi Khurana Khurana, Mwangi R, Ansell SM, Habermann TM, Cerhan JR, Strouse C, Link BK, Wang Y, King RL, Macon WR, Villasboas JC, Witzig TE, Maurer MJ, Nowakowski GS. Patterns of therapy initiation during the first decade for patients with follicular lymphoma who were observed at diagnosis in the rituximab era. Blood Cancer J. 2021 Jul 17; 11 (7):133 Epub 2021 July 17
    View PubMed
  80. Parikh SA, Rabe KG, Kay NE, Call TG, Ding W, Leis JF, Kenderian SS, Muchtar E, Wang Y, Koehler AB, Schwager SM, Lesnick CE, Kleinstern G, Van Dyke D, Hanson CA, Braggio E, Slager SL, Shanafelt TD. The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL. Blood. 2021 Jul 15; 138 (2):149-159
    View PubMed
  81. Wudhikarn K, Bansal R, Khurana A, Hathcock MA, Bennani NN, Paludo J, Villasboas JC, Wang Y, Johnston PB, Ansell SM, Lin Y. The impact of obesity and body weight on the outcome of patients with relapsed/refractory large B-cell lymphoma treated with axicabtagene ciloleucel. Blood Cancer J 2021 Jul 1; 11 (7):124 Epub 2021 July 01
    View PubMed
  82. Audil HY, Hampel PJ, Van Dyke DL, Achenbach SJ, Rabe KG, Smoley SA, Call TG, Ding W, Shi M, Hanson CA, Wang Y, Muchtar E, Koehler AB, Schwager SM, Leis JF, Braggio E, Slager SL, Kay NE, Kenderian SS, Parikh SA. The prognostic significance of del6q23 in chronic lymphocytic leukemia. Am J Hematol 2021 Jun 1; 96 (6):E203-E206 Epub 2021 Apr 07
    View PubMed
  83. Wang Y, Sinha S, Wellik LE, Secreto CR, Rech KL, Call TG, Parikh SA, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Van Dyke DL, Leis JF, Slager SL, Dong H, Kay NE, He R, Ding W. Distinct immune signatures in chronic lymphocytic leukemia and Richter syndrome. Blood Cancer J. 2021 May 10; 11 (5):86
    View PubMed
  84. Hampel PJ, Parikh SA, Call TG, Shah MV, Bennani NN, Al-Kali A, Rabe KG, Wang Y, Muchtar E, Leis JF, Kenderian SS, Koehler AB, Schwager SM, Slager SL, Kay NE, Hanson CA, Van Dyke DL, Shi M, Ding W. Venetoclax treatment of patients with relapsed T-cell prolymphocytic leukemia. Blood Cancer J 2021 Mar 2; 11 (3):47 Epub 2021 Mar 02
    View PubMed
  85. Castellino A, Tun AM, Wang Y, Habermann TM, King RL, Ristow KM, Cerhan JR, Inwards DJ, Paludo J, Ansell SM, Witzig TE, Nowakowski GS. Clinical characteristics and outcomes of primary versus secondary gastrointestinal mantle cell lymphoma. Blood Cancer J. 2021 Jan 7; 11 (1):8 Epub 2021 Jan 07
    View PubMed
  86. Archibald WJ, Rabe KG, Kabat BF, Herrmann J, Ding W, Kay NE, Kenderian SS, Muchtar E, Leis JF, Wang Y, Chanan-Khan AA, Schwager SM, Koehler AB, Fonder AL, Slager SL, Shanafelt TD, Call TG, Parikh SA. Atrial fibrillation in patients with chronic lymphocytic leukemia (CLL) treated with ibrutinib: risk prediction, management, and clinical outcomes. Ann Hematol. 2021 Jan; 100 (1):143-155 Epub 2020 June 01
    View PubMed
  87. Hampel PJ, Call TG, Rabe KG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia. Oncologist. 2020 Nov; 25 (11):974-980 Epub 2020 Sept 20
    View PubMed
  88. Wang Y, Rabe KG, Bold MS, Shi M, Hanson CA, Schwager SM, Call TG, Kenderian SS, Muchtar E, Hayman SR, Koehler AB, Fonder AL, Chanan-Khan AA, Van Dyke DL, Slager SL, Kay NE, Ding W, Leis JF, Parikh SA. The role of 18F-FDG-PET in detecting Richter's transformation of chronic lymphocytic leukemia in patients receiving therapy with a B-cell receptor inhibitor. Haematologica 2020 Nov 1; 105 (11):2675-2678 Epub 2020 Nov 01
    View PubMed
  89. Koehler AB, Leung N, Call TG, Rabe KG, Achenbach SJ, Ding W, Kenderian SS, Leis JF, Wang Y, Muchtar E, Hayman SR, Hampel PJ, Finnes HD, Schwager SM, Slager SL, Kay NE, Parikh SA. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice. Leuk Lymphoma. 2020 Oct; 61 (10):2383-2388 Epub 2020 May 25
    View PubMed
  90. Yang F, Markovic SN, Molina JR, Halfdanarson TR, Pagliaro LC, Chintakuntlawar AV, Li R, Wei J, Wang L, Liu B, Nowakowski GS, Wang ML, Wang Y. Association of Sex, Age, and Eastern Cooperative Oncology Group Performance Status With Survival Benefit of Cancer Immunotherapy in Randomized Clinical Trials: A Systematic Review and Meta-analysis. JAMA Netw Open. 2020 Aug 3; 3 (8):e2012534 Epub 2020 Aug 03
    View PubMed
  91. Hill HA, Qi X, Jain P, Nomie K, Wang Y, Zhou S, Wang ML. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020 Jul 14; 4 (13):2927-2938
    View PubMed
  92. Wang Y, Ding W. Richter transformation of chronic lymphocytic leukemia in the era of novel agents. Clin Adv Hematol Oncol. 2020 Jun; 18 (6):348-357
    View PubMed
  93. Ruan GJ, Mao JJ, Sytsma TT, Akogyeram II, Wang Y, Ashrani AA, Pruthi RK. Continuous infusion of recombinant porcine factor VIII for neurosurgical management of intracranial haemorrhage in a patient with severe haemophilia A with factor VIII inhibitor. Haemophilia 2020 May; 26 (3):e141-e144 Epub 2020 Mar 16
    View PubMed
  94. Zhang S, Kulkarni AA, Xu B, Chu H, Kourelis T, Go RS, Wang ML, Bachanova V, Wang Y. Bortezomib-based consolidation or maintenance therapy for multiple myeloma: a meta-analysis. Blood Cancer J. 2020 Mar 6; 10 (3):33 Epub 2020 Mar 06
    View PubMed
  95. Wang Y, Tschautscher MA, Rabe KG, Call TG, Leis JF, Kenderian SS, Kay NE, Muchtar E, Van Dyke DL, Koehler AB, Schwager SM, Slager SL, Parikh SA, Ding W. Clinical characteristics and outcomes of Richter transformation: experience of 204 patients from a single center. Haematologica. 2020 Mar; 105 (3):765-773 Epub 2019 June 13
    View PubMed
  96. Hampel PJ, Call TG, Ding W, Muchtar E, Kenderian SS, Wang Y, Leis JF, Witzig TE, Koehler AB, Fonder AL, Schwager SM, Rabe KG, Van Dyke DL, Braggio E, Slager SL, Kay NE, Parikh SA. Addition of venetoclax at time of progression in ibrutinib-treated patients with chronic lymphocytic leukemia: Combination therapy to prevent ibrutinib flare. Am J Hematol 2020 Mar; 95 (3):E57-E60 Epub 2019 Dec 13
    View PubMed
  97. Wang Y, Yang F, Wang ML. Immune Thrombocytopenia-A Neglected Adverse Event of PD-1 and PD-L1 Inhibitors in Clinical Trials-In Reply. JAMA Oncol. 2019 Nov 1; 5 (11):1641-1642
    View PubMed
  98. Wang Y, Link BK, Witzig TE, Maurer MJ, Allmer C, King RL, Feldman AL, Habermann TM, Ansell SM, Slager SL, Cerhan JR, Nowakowski GS. Impact of concurrent indolent lymphoma on the clinical outcome of newly diagnosed diffuse large B-cell lymphoma. Blood. 2019 Oct 17; 134 (16):1289-1297
    View PubMed
  99. Puffer RC, Spinner RJ, Bi H, Sharma R, Wang Y, Theis JD, McPhail ED, Poterucha JJ, Niu Z, Klein CJ. Fatal TTR amyloidosis with neuropathy from domino liver p.Val71Ala transplant. Neurol Genet. 2019 Oct; 5 (5):e351 Epub 2019 Aug 14
    View PubMed
  100. Wang Y, Maurer MJ, Larson MC, Allmer C, Feldman AL, Bennani NN, Thompson CA, Porrata LF, Habermann TM, Witzig TE, Ansell SM, Slager SL, Nowakowski GS, Cerhan JR. Impact of metformin use on the outcomes of newly diagnosed diffuse large B-cell lymphoma and follicular lymphoma. Br J Haematol. 2019 Sep; 186 (6):820-828 Epub 2019 May 28
    View PubMed
  101. Wang Y, Wenzl K, Manske MK, Asmann YW, Sarangi V, Greipp PT, Krull JE, Hartert K, He R, Feldman AL, Maurer MJ, Slager SL, Nowakowski GS, Habermann TM, Witzig TE, Link BK, Ansell SM, Cerhan JR, Novak AJ. Amplification of 9p24.1 in diffuse large B-cell lymphoma identifies a unique subset of cases that resemble primary mediastinal large B-cell lymphoma. Blood Cancer J. 2019 Aug 30; 9 (9):73
    View PubMed
  102. Wang Y, Farooq U, Link BK, Larson MC, King RL, Maurer MJ, Allmer C, Hefazi M, Thompson CA, Micallef IN, Johnston PB, Habermann TM, Witzig TE, Ansell SM, Cerhan JR, Nowakowski GS. Late Relapses in Patients With Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy. J Clin Oncol. 2019 Jul 20; 37 (21):1819-1827 Epub 2019 June 06
    View PubMed
  103. Wang Y, Zhou S, Yang F, Qi X, Wang X, Guan X, Shen C, Duma N, Vera Aguilera J, Chintakuntlawar A, Price KA, Molina JR, Pagliaro LC, Halfdanarson TR, Grothey A, Markovic SN, Nowakowski GS, Ansell SM, Wang ML. Treatment-Related Adverse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-analysis. JAMA Oncol. 2019 Jul 1; 5 (7):1008-1019
    View PubMed
  104. Wang Y, Habermann TM, Wang SS, Maurer MJ, Sarangi V, Link BK, Feldman AL, Inwards DJ, Witzig TE, Cozen W, Rothman N, Asmann Y, Slager SL, Cerhan JR. Host genetic variation in tumor necrosis factor and nuclear factor-kappaB pathways and overall survival in mantle cell lymphoma: A discovery and replication study. Am J Hematol 2019 Jun; 94 (6):E153-E155 Epub 2019 Mar 15
    View PubMed
  105. Wang Y, Jones JC, Jones JC, Kipp BR, Grothey A. Activity of EGFR antibody in non-V600 BRAF mutant metastatic colorectal cancer. Ann Oncol 2019 Jan 1; 30 (1):147-149
    View PubMed
  106. Edula RG, Muthukuru S, Moroianu S, Wang Y, Lingiah V, Fung P, Pyrsopoulos NT. CA-125 Significance in Cirrhosis and Correlation with Disease Severity and Portal Hypertension: A Retrospective Study. J Clin Transl Hepatol. 2018 Sep 28; 6 (3):241-246 Epub 2018 July 02
    View PubMed
  107. Wang Y, Nowakowski GS, Wang ML, Ansell SM. Advances in CD30- and PD-1-targeted therapies for classical Hodgkin lymphoma. J Hematol Oncol. 2018 Apr 23; 11 (1):57
    View PubMed
  108. Duma N, Vera Aguilera J, Paludo J, Haddox CL, Gonzalez Velez M, Wang Y, Leventakos K, Hubbard JM, Mansfield AS, Go RS, Adjei AA. Representation of Minorities and Women in Oncology Clinical Trials: Review of the Past 14 Years. J Oncol Pract. 2018 Jan; 14 (1):e1-e10 Epub 2017 Nov 03
    View PubMed
  109. Zhang W, Xu J, Fang H, Tang L, Chen W, Sun Q, Zhang Q, Yang F, Sun Z, Cao L, Wang Y, Guan X. Endothelial cells promote triple-negative breast cancer cell metastasis via PAI-1 and CCL5 signaling. FASEB J. 2018 Jan; 32 (1):276-288 Epub 2017 Sept 12
    View PubMed
  110. Yang F, Wang Y, Li Q, Cao L, Sun Z, Jin J, Fang H, Zhu A, Li Y, Zhang W, Wang Y, Xie H, Gustafsson JA, Wang S, Guan X. Intratumor heterogeneity predicts metastasis of triple-negative breast cancer. Carcinogenesis. 2017 Sep 1; 38 (9):900-909
    View PubMed
  111. Huang D, Yang F, Wang Y, Guan X. Mechanisms of resistance to selective estrogen receptor down-regulator in metastatic breast cancer. Biochim Biophys Acta Rev Cancer. 2017 Aug; 1868 (1):148-156 Epub 2017 Mar 23
    View PubMed
  112. Okoronkwo N, Wang Y, Pitchumoni C, Koneru B, Pyrsopoulos N. Improved Outcomes Following Hepatocellular Carcinoma (HCC) Diagnosis in Patients Screened for HCC in a Large Academic Liver Center versus Patients Identified in the Community. J Clin Transl Hepatol. 2017 Mar 28; 5 (1):31-34 Epub 2017 Feb 22
    View PubMed
  113. Wang Y, Sanchez L, Siegel DS, Wang ML. Elotuzumab for the treatment of multiple myeloma. J Hematol Oncol. 2016 Jul 15; 9 (1):55 Epub 2016 July 15
    View PubMed
  114. Sanchez L, Wang Y, Siegel DS, Wang ML. Daratumumab: a first-in-class CD38 monoclonal antibody for the treatment of multiple myeloma. J Hematol Oncol. 2016 Jun 30; 9 (1):51 Epub 2016 June 30
    View PubMed
  115. Zhang W, Cao L, Sun Z, Xu J, Tang L, Chen W, Luo J, Yang F, Wang Y, Guan X. Skp2 is over-expressed in breast cancer and promotes breast cancer cell proliferation. Cell Cycle. 2016 May 18; 15 (10):1344-51 Epub 2016 Apr 25
    View PubMed
  116. Wang Y, Yang F, Shen Y, Zhang W, Wang J, Chang VT, Andersson BS, Qazilbash MH, Champlin RE, Berenson JR, Guan X, Wang ML. Maintenance Therapy With Immunomodulatory Drugs in Multiple Myeloma: A Meta-Analysis and Systematic Review. J Natl Cancer Inst. 2016 Mar; 108 (3) Epub 2015 Nov 18
    View PubMed
  117. Zhang W, Luo J, Yang F, Wang Y, Yin Y, Strom A, Gustafsson JA, Guan X. BRCA1 inhibits AR-mediated proliferation of breast cancer cells through the activation of SIRT1. Sci Rep. 2016 Feb 23; 6:22034
    View PubMed
  118. Imran TF, Wang Y, Zhang S, Hussain MU, Srinivas S. A Baffled Mind: A Mysterious Presentation of Small-Cell Carcinoma of the Bladder. Clin Genitourin Cancer. 2015 Aug; 13 (4):e329-e332 Epub 2015 Feb 07
    View PubMed
  119. Wang Y, Zhang LL, Champlin RE, Wang ML. Targeting Bruton's tyrosine kinase with ibrutinib in B-cell malignancies. Clin Pharmacol Ther. 2015 May; 97 (5):455-68 Epub 2015 Apr 03
    View PubMed
  120. Weber DC, Wang Y, Miller R, Villa S, Zaucha R, Pica A, Poortmans P, Anacak Y, Ozygit G, Baumert B, Haller G, Preusser M, Li J. Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. Neuro Oncol. 2015 Apr; 17 (4):588-95 Epub 2014 Oct 09
    View PubMed
  121. Nie W, Huang W, Zhang W, Xu J, Song W, Wang Y, Zhu A, Luo J, Huang G, Wang Y, Guan X. TXNIP interaction with the Her-1/2 pathway contributes to overall survival in breast cancer. Oncotarget. 2015 Feb 20; 6 (5):3003-12
    View PubMed
  122. Tsai CJ, Wang Y, Allen PK, Mahajan A, McCutcheon IE, Rao G, Rhines LD, Tatsui CE, Armstrong TS, Maor MH, Chang EL, Brown PD, Li J. Outcomes after surgery and radiotherapy for spinal myxopapillary ependymoma: update of the MD Anderson Cancer Center experience. Neurosurgery. 2014 Sep; 75: (3)205-14; discussion 213-4.
    View PubMed
  123. Lai J, Nie W, Zhang W, Wang Y, Xie R, Wang Y, Gu J, Xu J, Song W, Yang F, Huang G, Cao P, Guan X. Transcriptional regulation of the p73 gene by Nrf-2 and promoter CpG methylation in human breast cancer. Oncotarget. 2014 Aug 30; 5 (16):6909-22
    View PubMed
  124. Castillo A, Paul A, Sun B, Huang TH, Wang Y, Yazinski SA, Tyler J, Li L, You MJ, Zou L, Yao J, Wang B. The BRCA1-interacting protein Abraxas is required for genomic stability and tumor suppression. Cell Rep. 2014 Aug 7; 8 (3):807-17 Epub 2014 July 24
    View PubMed
  125. Huang Y, Leung JW, Lowery M, Matsushita N, Wang Y, Shen X, Huong D, Takata M, Chen J, Li L. Modularized functions of the Fanconi anemia core complex. Cell Rep. 2014 Jun 26; 7 (6):1849-57 Epub 2014 June 05
    View PubMed
  126. Smith S, Fox J, Mejia M, Ruangpradit W, Saberi A, Kim S, Choi Y, Oh S, Wang Y, Choi K, Li L, Hendrickson EA, Takeda S, Muller M, Myung K. Histone deacetylase inhibitors selectively target homology dependent DNA repair defective cells and elevate non-homologous endjoining activity. PLoS One. 2014; 9 (1):e87203 Epub 2014 Jan 23
    View PubMed
  127. Wang Y, Han X, Wu F, Leung JW, Lowery MG, Do H, Chen J, Shi C, Tian C, Li L, Gong W. Structure analysis of FAAP24 reveals single-stranded DNA-binding activity and domain functions in DNA damage response. Cell Res. 2013 Oct; 23 (10):1215-28 Epub 2013 Sept 03
    View PubMed
  128. Tang L, Wang Y, Strom A, Gustafsson JA, Guan X. Lapatinib induces p27(Kip1)-dependent G(1) arrest through both transcriptional and post-translational mechanisms. Cell Cycle. 2013 Aug 15; 12 (16):2665-74 Epub 2013 July 29
    View PubMed
  129. Wang Y, Leung JW, Jiang Y, Lowery MG, Do H, Vasquez KM, Chen J, Wang W, Li L. FANCM and FAAP24 maintain genome stability via cooperative as well as unique functions. Mol Cell. 2013 Mar 7; 49 (5):997-1009 Epub 2013 Jan 17
    View PubMed
  130. Gou W, Xu L, Wang Y, Yu W, Zhong Z, Gao J, Chen H, Wang Y. Mitochondrial protective effects of Myrica rubra extract against acetaminophen-induced toxicity. Am J Chin Med. 2013; 41 (5):1053-64
    View PubMed
  131. Wei F, Xu J, Tang L, Shao J, Wang Y, Chen L, Guan X. p27(Kip1) V109G polymorphism and cancer risk: a systematic review and meta-analysis. Cancer Biother Radiopharm. 2012 Dec; 27 (10):665-71 Epub 2012 July 23
    View PubMed
  132. Lu W, Chen Z, Zhang H, Wang Y, Luo Y, Huang P. ZNF143 transcription factor mediates cell survival through upregulation of the GPX1 activity in the mitochondrial respiratory dysfunction. Cell Death Dis. 2012 Nov 15; 3:e422
    View PubMed
  133. Yan Z, Guo R, Paramasivam M, Shen W, Ling C, Fox D 3rd, Wang Y, Oostra AB, Kuehl J, Lee DY, Takata M, Hoatlin ME, Schindler D, Joenje H, de Winter JP, Li L, Seidman MM, Wang W. A ubiquitin-binding protein, FAAP20, links RNF8-mediated ubiquitination to the Fanconi anemia DNA repair network. Mol Cell. 2012 Jul 13; 47 (1):61-75 Epub 2012 June 14
    View PubMed
  134. Nie W, Tang L, Zhang H, Shao J, Wang Y, Chen L, Li D, Guan X. Structural analysis of the EGFR TK domain and potential implications for EGFR targeted therapy. Int J Oncol. 2012 Jun; 40 (6):1763-9 Epub 2012 Feb 03
    View PubMed
  135. Leung JW, Wang Y, Fong KW, Huen MS, Li L, Chen J. Fanconi anemia (FA) binding protein FAAP20 stabilizes FA complementation group A (FANCA) and participates in interstrand cross-link repair. Proc Natl Acad Sci U S A. 2012 Mar 20; 109 (12):4491-6 Epub 2012 Mar 06
    View PubMed
  136. Xu L, Qin W, Zhang H, Wang Y, Dou H, Yu D, Ding Y, Yang L, Wang Y. Alterations in microRNA expression linked to microcystin-LR-induced tumorigenicity in human WRL-68 Cells. Mutat Res. 2012 Mar 18; 743 (1-2):75-82 Epub 2012 Jan 14
    View PubMed
  137. Chen W, Wei F, Xu J, Wang Y, Chen L, Wang J, Guan X. Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line. Int J Mol Med. 2011 Dec; 28 (6):985-91 Epub 2011 Sept 01
    View PubMed
  138. Wang Y, Li L. Detecting recruitment of DNA damage response factors through the eChIP approach. Methods Mol Biol. 2011; 782:245-55.
    View PubMed
  139. Xu L, Gao J, Wang Y, Yu W, Zhao X, Yang X, Zhong Z, Qian ZM. Myrica rubra Extracts Protect the Liver from CCl(4)-Induced Damage. Evid Based Complement Alternat Med. 2011; 2011:518302 Epub 2011 Feb 14
    View PubMed
  140. Guan X, Wang Y, Xie R, Chen L, Bai J, Lu J, Kuo MT. p27(Kip1) as a prognostic factor in breast cancer: a systematic review and meta-analysis. J Cell Mol Med. 2010 Apr; 14 (4):944-53 Epub 2010 Feb 27
    View PubMed
  141. Wang YC, Yu ZH, Liu C, Xu LZ, Yu W, Lu J, Zhu RM, Li GL, Xia XY, Wei XW, Ji HZ, Lu H, Gao Y, Gao WM, Chen LB. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J Gastroenterol. 2008 May 21; 14 (19):3074-80
    View PubMed
  142. Chen LB, Tong JL, Song HZ, Zhu H, Wang YC. (18)F-DG PET/CT in detection of recurrence and metastasis of colorectal cancer. World J Gastroenterol. 2007 Oct 7; 13 (37):5025-9
    View PubMed
  143. Wang Y, Yu Z, Wang T, Zhang J, Hong L, Chen L. Identification of epigenetic aberrant promoter methylation of RASSF1A in serum DNA and its clinicopathological significance in lung cancer. Lung Cancer. 2007 May; 56 (2):289-94 Epub 2007 Jan 30
    View PubMed
PST-20464666